CD274 and neoplasm: Early findings from an ongoing phase I study affirmed the blockade of PD-L1/PD-1 in peripheral blood cells, showing heightened immune activation and effective control of tumor growth, providing a basis for a further clinical assessment of INCB086550 as a potential alternative to antibody-based therapies [46].